Valensa International (Eustis, FL USA) announced today that it has entered into a license agreement with Biova, LLC (Johnston, Iowa USA) that will allow Valensa to include the patented BiovaFlex(TM) water-soluble egg shell membrane ingredient in a proprietary new series of formulated joint health products. In addition Valensa was granted a worldwide exclusive license for BiovaFlex in gummy-type chewables for joint health. In late 2009, Valensa announced that it had developed and filed provisional patents for a revolutionary range of joint, cardiovascular and eye health care dietary supplement and medical food formulations featuring Aker Biomarine krill oil and other scientifically sound condition-specific ingredients. The agreement with Biova is a continuation of Valensa's program in the area of joint health. Valensa is currently discussing joint health formulations with select marketing partners and will announce commercial products in Q2 2010.
According to Dr. Rudi E. Moerck, President & CEO, the joint health market is currently a major focus at Valensa. "Today, more than 140 million adults in the U.S., and many times that around the world, suffer from some form of joint or connective tissue issues. As our population ages, this estimate is expected to grow rapidly. There is a substantial opportunity to improve the quality of life for millions of people by applying sound science to joint health," he said. "We are pleased to have an agreement with Biova on this science-based and patented ingredient that competitively enhances our joint health product formulation capabilities. Our goal is to use BiovaFlex and our own proprietary ingredients, including astaxanthin and krill oil, to create revolutionary joint health formulations that feature vastly smaller dosage requirements and easy-to-consume dosage forms such as gummies, small capsules, tablets or softgels," he added.